Cycrimine is a drug used to reduce levels of acetylcholine to return a balance with dopamine in the treatment and management of Parkinson's disease.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Aclidinium | The risk or severity of adverse effects can be increased when Cycrimine is combined with Aclidinium. |
| Mianserin | Mianserin may increase the anticholinergic activities of Cycrimine. |
| Mirabegron | The risk or severity of urinary retention can be increased when Cycrimine is combined with Mirabegron. |
| Potassium chloride | The risk or severity of gastrointestinal ulceration can be increased when Cycrimine is combined with Potassium chloride. |
| Pramlintide | The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Cycrimine. |
| Secretin porcine | The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Cycrimine. |
| Tiotropium | The risk or severity of adverse effects can be increased when Cycrimine is combined with Tiotropium. |
| Topiramate | The risk or severity of hyperthermia and oligohydrosis can be increased when Cycrimine is combined with Topiramate. |
| Umeclidinium | The risk or severity of adverse effects can be increased when Cycrimine is combined with Umeclidinium. |
| Glycopyrronium | The risk or severity of adverse effects can be increased when Cycrimine is combined with Glycopyrronium. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Cycrimine is combined with Botulinum toxin type A. |
| Glucagon | Cycrimine may increase the gastrointestinal motility reducing activities of Glucagon. |
| Sulpiride | Cycrimine may increase the anticholinergic activities of Sulpiride. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Cycrimine is combined with Botulinum toxin type B. |
| Eluxadoline | The risk or severity of constipation can be increased when Cycrimine is combined with Eluxadoline. |
| Ramosetron | The risk or severity of constipation can be increased when Cycrimine is combined with Ramosetron. |
| Naltrexone | The risk or severity of adverse effects can be increased when Cycrimine is combined with Naltrexone. |
| Bezitramide | The risk or severity of adverse effects can be increased when Cycrimine is combined with Bezitramide. |
| Tramadol | The risk or severity of adverse effects can be increased when Cycrimine is combined with Tramadol. |
| Morphine | The risk or severity of adverse effects can be increased when Cycrimine is combined with Morphine. |
| Codeine | The risk or severity of adverse effects can be increased when Cycrimine is combined with Codeine. |
| Hydromorphone | The risk or severity of adverse effects can be increased when Cycrimine is combined with Hydromorphone. |
| Methadone | The risk or severity of adverse effects can be increased when Cycrimine is combined with Methadone. |
| Meperidine | The risk or severity of adverse effects can be increased when Cycrimine is combined with Meperidine. |
| Oxycodone | The risk or severity of adverse effects can be increased when Cycrimine is combined with Oxycodone. |
| Butorphanol | The risk or severity of adverse effects can be increased when Cycrimine is combined with Butorphanol. |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Cycrimine is combined with Dextropropoxyphene. |
| Pentazocine | The risk or severity of adverse effects can be increased when Cycrimine is combined with Pentazocine. |
| Sufentanil | The risk or severity of adverse effects can be increased when Cycrimine is combined with Sufentanil. |
| Alfentanil | The risk or severity of adverse effects can be increased when Cycrimine is combined with Alfentanil. |
| Fentanyl | The risk or severity of adverse effects can be increased when Cycrimine is combined with Fentanyl. |
| Nalbuphine | The risk or severity of adverse effects can be increased when Cycrimine is combined with Nalbuphine. |
| Levorphanol | The risk or severity of adverse effects can be increased when Cycrimine is combined with Levorphanol. |
| Remifentanil | The risk or severity of adverse effects can be increased when Cycrimine is combined with Remifentanil. |
| Buprenorphine | The risk or severity of adverse effects can be increased when Cycrimine is combined with Buprenorphine. |
| Hydrocodone | The risk or severity of adverse effects can be increased when Cycrimine is combined with Hydrocodone. |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Cycrimine is combined with Diphenoxylate. |
| Oxymorphone | The risk or severity of adverse effects can be increased when Cycrimine is combined with Oxymorphone. |
| Dezocine | The risk or severity of adverse effects can be increased when Cycrimine is combined with Dezocine. |
| Levacetylmethadol | The risk or severity of adverse effects can be increased when Cycrimine is combined with Levacetylmethadol. |
| Methadyl acetate | The risk or severity of adverse effects can be increased when Cycrimine is combined with Methadyl acetate. |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Cycrimine is combined with Dihydroetorphine. |
| Diamorphine | The risk or severity of adverse effects can be increased when Cycrimine is combined with Diamorphine. |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Cycrimine is combined with Ethylmorphine. |
| Etorphine | The risk or severity of adverse effects can be increased when Cycrimine is combined with Etorphine. |
| Dextromoramide | The risk or severity of adverse effects can be increased when Cycrimine is combined with Dextromoramide. |
| Desomorphine | The risk or severity of adverse effects can be increased when Cycrimine is combined with Desomorphine. |
| Carfentanil | The risk or severity of adverse effects can be increased when Cycrimine is combined with Carfentanil. |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Cycrimine is combined with Dihydrocodeine. |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Cycrimine is combined with Alphacetylmethadol. |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Cycrimine is combined with Dihydromorphine. |
| Tapentadol | The risk or severity of urinary retention and constipation can be increased when Cycrimine is combined with Tapentadol. |
| Ketobemidone | The risk or severity of adverse effects can be increased when Cycrimine is combined with Ketobemidone. |
| DPDPE | The risk or severity of adverse effects can be increased when Cycrimine is combined with DPDPE. |
| Lofentanil | The risk or severity of adverse effects can be increased when Cycrimine is combined with Lofentanil. |
| Opium | The risk or severity of adverse effects can be increased when Cycrimine is combined with Opium. |
| Normethadone | The risk or severity of adverse effects can be increased when Cycrimine is combined with Normethadone. |
| Piritramide | The risk or severity of adverse effects can be increased when Cycrimine is combined with Piritramide. |
| Alphaprodine | The risk or severity of adverse effects can be increased when Cycrimine is combined with Alphaprodine. |
| Nicomorphine | The risk or severity of adverse effects can be increased when Cycrimine is combined with Nicomorphine. |
| Meptazinol | The risk or severity of adverse effects can be increased when Cycrimine is combined with Meptazinol. |
| Phenoperidine | The risk or severity of adverse effects can be increased when Cycrimine is combined with Phenoperidine. |
| Phenazocine | The risk or severity of adverse effects can be increased when Cycrimine is combined with Phenazocine. |
| Tilidine | The risk or severity of adverse effects can be increased when Cycrimine is combined with Tilidine. |
| Carfentanil, C-11 | The risk or severity of adverse effects can be increased when Cycrimine is combined with Carfentanil, C-11. |
| Benzhydrocodone | The risk or severity of adverse effects can be increased when Cycrimine is combined with Benzhydrocodone. |
| Naloxegol | The risk or severity of adverse effects can be increased when Cycrimine is combined with Naloxegol. |
| Trospium | The risk or severity of adverse effects can be increased when Trospium is combined with Cycrimine. |
| Oxyphenonium | The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Cycrimine. |
| Benzatropine | The risk or severity of adverse effects can be increased when Benzatropine is combined with Cycrimine. |
| Disopyramide | The risk or severity of adverse effects can be increased when Disopyramide is combined with Cycrimine. |
| Metixene | The risk or severity of adverse effects can be increased when Metixene is combined with Cycrimine. |
| Terfenadine | The risk or severity of adverse effects can be increased when Terfenadine is combined with Cycrimine. |
| Buclizine | The risk or severity of adverse effects can be increased when Buclizine is combined with Cycrimine. |
| Trihexyphenidyl | The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Cycrimine. |
| Oxyphencyclimine | The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Cycrimine. |
| Procyclidine | The risk or severity of adverse effects can be increased when Procyclidine is combined with Cycrimine. |
| Hyoscyamine | The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Cycrimine. |
| Methscopolamine bromide | The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Cycrimine. |
| Darifenacin | The risk or severity of adverse effects can be increased when Darifenacin is combined with Cycrimine. |
| Tridihexethyl | The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Cycrimine. |
| Anisotropine methylbromide | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Cycrimine. |
| Atropine | The risk or severity of adverse effects can be increased when Atropine is combined with Cycrimine. |
| Nicardipine | The risk or severity of adverse effects can be increased when Nicardipine is combined with Cycrimine. |
| Mecamylamine | The risk or severity of adverse effects can be increased when Mecamylamine is combined with Cycrimine. |
| Pirenzepine | The risk or severity of adverse effects can be increased when Pirenzepine is combined with Cycrimine. |
| Homatropine methylbromide | The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Cycrimine. |
| Benzquinamide | The risk or severity of adverse effects can be increased when Benzquinamide is combined with Cycrimine. |
| Propantheline | The risk or severity of adverse effects can be increased when Propantheline is combined with Cycrimine. |
| Dicyclomine | The risk or severity of adverse effects can be increased when Dicyclomine is combined with Cycrimine. |
| Tropicamide | The risk or severity of adverse effects can be increased when Tropicamide is combined with Cycrimine. |
| Cocaine | The risk or severity of adverse effects can be increased when Cocaine is combined with Cycrimine. |
| Quinidine | The risk or severity of adverse effects can be increased when Quinidine is combined with Cycrimine. |
| Amantadine | The risk or severity of adverse effects can be increased when Amantadine is combined with Cycrimine. |
| Methantheline | The risk or severity of adverse effects can be increased when Methantheline is combined with Cycrimine. |
| Cyclopentolate | The risk or severity of adverse effects can be increased when Cycrimine is combined with Cyclopentolate. |
| Tolterodine | The risk or severity of adverse effects can be increased when Cycrimine is combined with Tolterodine. |
| Oxybutynin | The risk or severity of adverse effects can be increased when Cycrimine is combined with Oxybutynin. |
| Pentolinium | The risk or severity of adverse effects can be increased when Cycrimine is combined with Pentolinium. |
| Trimethaphan | The risk or severity of adverse effects can be increased when Cycrimine is combined with Trimethaphan. |